Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Proliferative and anti-proliferative effects of dietary levels of phytoestrogens in rat pituitary GH3/B6/F10cells - the involvement of rapidly activated kinases and caspases

Authors: Yow-Jiun Jeng, Cheryl S Watson

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Phytoestogens are a group of lipophillic plant compounds that can have estrogenic effects in animals; both tumorigenic and anti-tumorigenic effects have been reported. Prolactin-secreting adenomas are the most prevalent form of pituitary tumors in humans and have been linked to estrogen exposures. We examined the proliferative effects of phytoestrogens on a rat pituitary tumor cell line, GH3/B6/F10, originally subcloned from GH3 cells based on its ability to express high levels of the membrane estrogen receptor-α.

Methods

We measured the proliferative effects of these phytoestrogens using crystal violet staining, the activation of several mitogen-activated protein kinases (MAPKs) and their downstream targets via a quantitative plate immunoassay, and caspase enzymatic activities.

Results

Four phytoestrogens (coumestrol, daidzein, genistein, and trans-resveratrol) were studied over wide concentration ranges. Except trans-resveratrol, all phytoestrogens increased GH3/B6/F10 cell proliferation at some concentration relevant to dietary levels. All four phytoestrogens attenuated the proliferative effects of estradiol when administered simultaneously. All phytoestrogens elicited MAPK and downstream target activations, but with time course patterns that often differed from that of estradiol and each other. Using selective antagonists, we determined that MAPKs play a role in the ability of these phytoestrogens to elicit these responses. In addition, except for trans-resveratrol, a serum removal-induced extrinsic apoptotic pathway was blocked by these phytoestrogens.

Conclusion

Phytoestrogens can block physiological estrogen-induced tumor cell growth in vitro and can also stimulate growth at high dietary concentrations in the absence of endogenous estrogens; these actions are correlated with slightly different signaling response patterns. Consumption of these compounds should be considered in strategies to control endocrine tumor cell growth, such as in the pituitary.
Appendix
Available only for authorised users
Literature
1.
Cornwell T, Cohick W, Raskin I: Dietary phytoestrogens and health. Phytochemistry. 2004, 65: 995-1016. 10.1016/j.phytochem.2004.03.005.CrossRefPubMed
2.
Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF, Mabry TJ: Flavonoid effects relevant to cancer. J Nutr. 2002, 132: 3482S-3489S.PubMed
3.
Fritz WA, Coward L, Wang J, Lamartiniere CA: Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis. 1998, 19: 2151-2158. 10.1093/carcin/19.12.2151.CrossRefPubMed
4.
Gooren LJ, Giltay EJ, Bunck MC: Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab. 2008, 93: 19-25. 10.1210/jc.2007-1809.CrossRefPubMed
5.
Harris DM, Besselink E, Henning SM, Go VLW, Heber D: Phytoestrogens Induce Differential Estrogen Receptor Alpha- or Beta-Mediated Responses in Transfected Breast Cancer Cells. Experimental Biology and Medicine. 2005, 230: 558-568.PubMed
6.
Whitten PL, Lewis C, Russell E, Naftolin F: Phytoestrogen influences on the development of behavior and gonadotropin function. Proceedings of the Society for Experimental Biology & Medicine. 1995, 208: 82-86.CrossRef
7.
Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al: The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004, 279: 27008-27016.CrossRefPubMed
8.
Bulayeva NN, Wozniak A, Lash LL, Watson CS: Mechanisms of membrane estrogen receptor-{alpha}-mediated rapid stimulation of Ca2+ levels and prolactin release in a pituitary cell line. Am J Physiol Endocrinol Metab. 2005, 288: E388-E397.CrossRefPubMed
9.
Pappas TC, Gametchu B, Watson CS: Membrane estrogen receptor-enriched GH3/B6 cells have an enhanced non-genomic response to estrogen. Endocrine. 1995, 3: 743-749.CrossRefPubMed
10.
Bulayeva NN, Gametchu B, Watson CS: Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Steroids. 2004, 69: 181-192.CrossRefPubMedPubMedCentral
11.
Bickoff EM, Booth AN, Lyman RL, Livingston AL, Thompson CR, Deeds F: Coumestrol, a new estrogen isolated from forage crops. Science. 1957, 126: 969-970.CrossRefPubMed
12.
Mustafa AM, Malintan NT, Seelan S, Zhan Z, Mohamed Z, Hassan J, et al: Phytoestrogens levels determination in the cord blood from Malaysia rural and urban populations. Toxicology and Applied Pharmacology. 2007, 222: 25-32.CrossRefPubMed
13.
14.
Adlercreutz H, Fotsis T, Lampe J, Wahala K, Makela T, Brunow G, et al: Quantitative determination of lignans and isoflavonoids in plasma of omnivorous and vegetarian women by isotope dilution gas chromatography-mass spectrometry. Scand J Clin Lab Invest Suppl. 1993, 215: 5-18.CrossRefPubMed
15.
Gehm BD, McAndrews JM, Chien PY, Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA. 1997, 94: 14138-14143.CrossRefPubMedPubMedCentral
16.
Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK: HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS. Drug Metab Dispos. 2004, 32: 1377-1382.CrossRefPubMed
17.
Hernandez M, Soto-Cid A, Rojas F, Pascual L, randa-Abreu G, Toledo R, et al: Prostate response to prolactin in sexually active male rats. Reproductive Biology and Endocrinology. 2006, 4: 28-CrossRefPubMedPubMedCentral
18.
Torner L, Toschi N, Pohlinger A, Landgraf R, Neumann ID: Anxiolytic and anti-stress effects of brain prolactin: Improved efficacy of antisense targeting of the prolactin receptor by molecular modeling. Journal of Neuroscience. 2001, 21: 3207-3214.PubMed
19.
Wiklund J, Wertz N, Gorski J: A comparison of estrogen effects on uterine and pituitary growth and prolactin synthesis in F344 and Holtzman rats. Endocr. 1981, 109: 1700-1707.CrossRef
20.
Gorski J, Wendell D, Gregg D, Chun TY: Estrogens and the genetic control of tumor growth. [Review] [[23] refs]. Progress in Clinical & Biological Research. 1997, 396: 233-243.
21.
Sarkar DK, Hentges ST, De A, Reddy RH: Hormonal control of pituitary prolactin-secreting tumors. Front Biosci. 1998, 3: d934-d943.CrossRefPubMed
22.
Hommes DW, Peppelenbosch MP, van Deventer SJH: Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut. 2003, 52: 144-151.CrossRefPubMedPubMedCentral
23.
Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, et al: Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol. 2008, 630: 19-34.CrossRefPubMedPubMedCentral
24.
25.
Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, et al: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002, 80: 239-256.CrossRefPubMed
26.
Bulayeva NN, Watson CS: Xenoestrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Environ Health Perspect. 2004, 112: 1481-1487.CrossRefPubMedPubMedCentral
27.
Belcher SM, Zsarnovszky A: Estrogenic actions in the brain: estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther. 2001, 299: 408-414.PubMed
28.
Cato AC, Nestl A, Mink S: Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE. 2002, 2002: RE9-PubMed
29.
Ho KJ, Liao JK: Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol. 2002, 22: 1952-1961.CrossRefPubMed
30.
Watson CS, Jeng YJ, Kochukov MY: Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. The FASEB Journal. 2008, 22: 3328-3336.CrossRefPubMedPubMedCentral
31.
Zhou JH, Yu DV, Cheng J, Shapiro DJ: Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death. Steroids. 2007, 72: 765-777.CrossRefPubMedPubMedCentral
32.
Gibson MK, Nemmers LA, Beckman WC, Davis VL, Curtis SW, Korach KS: The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocr. 1991, 129: 2000-2010.CrossRef
33.
Bulayeva N, Gametchu B, Watson CS: Xenoestrogens can activate MAP kinases in a pituitary tumor cell line. FASEB Summer Conference on Steroid Receptors in the Plasma Membrane [Snow Mass, CO]. 2002, Ref Type: Abstract
34.
Watson CS, Bulayeva NN, Wozniak AL, Alyea RA: Xenoestrogens are potent activators of nongenomic estrogenic responses PMCID:17174995. Steroids. 2007, 72: 124-134.CrossRefPubMed
35.
Watson CS, Alyea RA, Jeng YJ, Kochukov MY: Nongenomic actions of low concentration estrogens and xenoestrogens on multiple tissues PMCID:17601655. Mol Cell Endocrinol. 2007, 274: 1-7.CrossRefPubMedPubMedCentral
36.
Watson CS, Jeng YJ, Kochukov MY: Nongenomic actions of estradiol compared with estrone and estriol in pituitary tumor cell signaling and proliferation. FASEB J. 2008, 22: 3328-3336.CrossRefPubMedPubMedCentral
37.
Greenspan FS, Gardner DG: Appendix: Normal Hormone Reference Ranges. Basic and Clinical Endocrinology. Edited by: Greenspan FS, Gardner DG. 2004, New York: Lange Medical Books, McGraw Hill, 925-926. 7
38.
Watson CS, Norfleet AM, Pappas TC, Gametchu B: Rapid actions of estrogens in GH3/B6 pituitiary tumor cells via a plasma membrane version of estrogen receptor-∀. Steroids. 1999, 64: 5-13.CrossRefPubMed
39.
Watson CS, Zivadinovic D, Bulayeva N, Hawkins B, Campbell CH, Gametchu B: A membrane form of estrogen receptor-α mediates estrogenic, nongenomic effects. The Identitities of Membrane Steroid Receptors. Edited by: Watson CS. 2003, Boston: Kluwer Academic Publishers, 11-19.CrossRef
40.
Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC: Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens PMCID:15862819. Steroids. 2005, 70: 364-371.CrossRefPubMed
41.
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocr. 1997, 138: 863-870.
42.
Alblas J, Slager-Davidov R, Steenbergh PH, Sussenbach JS, van der BB: The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene. 1998, 16: 131-139.CrossRefPubMed
43.
Zivadinovic D, Watson CS: Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1/2 activation in MCF-7 cells. Breast Cancer Res. 2005, 7: R130-R144.CrossRefPubMed
44.
Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J: Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol. 2002, 4: 556-564.PubMed
45.
Kanasaki H, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E: Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells. Biol Reprod. 2000, 62: 1486-1494.CrossRefPubMed
46.
Chuang SM, Wang IC, Yang JL: Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium. Carcinogenesis. 2000, 21: 1423-1432.CrossRefPubMed
47.
Ban N, Yamada Y, Someya Y, Ihara Y, Adachi T, Kubota A, et al: Activating transcription factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression. Diabetes. 2000, 49: 1142-1148.CrossRefPubMed
48.
Jeng YJ, Kochukov MY, Watson CS: Membrane estrogen receptor-alpha-mediated nongenomic actions of phytoestrogens in GH3/B6/F10 pituitary tumor cells. J Mol Signal. 2009, 4: 2-CrossRefPubMedPubMedCentral
49.
Schamberger CJ, Gerner C, Cerni C: Caspase-9 plays a marginal role in serum starvation-induced apoptosis. Experimental Cell Research. 2005, 302: 115-128.CrossRefPubMed
50.
Campbell CH, Watson CS: A comparison of membrane vs. intracellular estrogen receptor-∀ in GH3/B6 pituitary tumor cells using a quantitative plate immunoassay PMCID:11522334. Steroids. 2001, 66: 727-736.CrossRefPubMed
51.
Norfleet AM, Thomas ML, Gametchu B, Watson CS: Estrogen receptor-α detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary cells by enzyme-linked immunocytochemistry PMCID:10433242. Endocr. 1999, 140: 3805-3814.
52.
Norfleet AM, Clarke C, Gametchu B, Watson CS: Antibodies to the estrogen receptor-α modulate prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors PMCID:10627290. FASEB J. 2000, 14: 157-165.PubMedPubMedCentral
53.
Wozniak AL, Bulayeva NN, Watson CS: Xenoestrogens at picomolar to nanomolar concentrations trigger membrane estrogen receptor-alpha-mediated Ca2+ fluxes and prolactin release in GH3/B6 pituitary tumor cells PMCID:15811834. Environ Health Perspect. 2005, 113: 431-439.CrossRefPubMedPubMedCentral
54.
Gametchu B, Watson CS: Correlation of membrane glucocorticoid receptor levels with glucocorticoid-induced apoptotic competence using mutant leukemic and lymphoma cells lines. Journal of Cellular Biochemistry. 2002, 87: 133-146.CrossRefPubMed
55.
Go VL, Butrum RR, Norman HA: Review of the International Research Conference on Food, Nutrition, and Cancer, 2005. J Nutr. 2005, 135: 2925S-2926S.PubMed
Metadata
Title
Proliferative and anti-proliferative effects of dietary levels of phytoestrogens in rat pituitary GH3/B6/F10cells - the involvement of rapidly activated kinases and caspases
Authors
Yow-Jiun Jeng
Cheryl S Watson
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-334

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study

Research article

Nuclear receptor coregulator SNP discovery and impact on breast cancer risk

Research article

CYP17, GSTP1, PON1 and GLO1gene polymorphisms as risk factors for breast cancer: an Italian case-control study

Research article

Triple negative breast carcinoma is a prognostic factor in Taiwanese women

Research article

ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma

Research article

Pre-radiotherapy plasma carotenoids and markers of oxidative stress are associated with survival in head and neck squamous cell carcinoma patients: a prospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits